Hybrid Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffolds in Combination With Drug-Eluting Stents or Drug-Coated Balloons for Complex Coronary Lesions

JACC Cardiovasc Interv. 2017 Mar 27;10(6):539-547. doi: 10.1016/j.jcin.2016.12.285.

Abstract

Bioresorbable vascular scaffolds (BVS) have become an attractive option in the percutaneous coronary intervention field due to the potential advantages associated with the complete resorption process that occurs within a few years. However, current-generation BVS have several limitations including thicker struts, reduced radial strength, and limited expansion capability when compared with drug-eluting stents (DES). As a result, complex coronary disease often contains BVS-inappropriate/unfavorable segments. This does not necessarily mean that BVS use must be completely avoided, and minimizing the length of permanent metallic caging may still be advantageous. Operators should fully understand the limitations of current BVS, and when to consider a hybrid strategy of BVS in combination with DES or drug-coated balloons.

Keywords: bioresorbable scaffold; drug-coated balloon; drug-eluting stent(s).

Publication types

  • Review

MeSH terms

  • Absorbable Implants*
  • Angioplasty, Balloon, Coronary / adverse effects
  • Angioplasty, Balloon, Coronary / instrumentation*
  • Cardiac Catheters*
  • Cardiovascular Agents / administration & dosage*
  • Cardiovascular Agents / adverse effects
  • Coated Materials, Biocompatible*
  • Coronary Angiography
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / therapy*
  • Drug-Eluting Stents*
  • Humans
  • Patient Selection
  • Prosthesis Design
  • Risk Assessment
  • Risk Factors
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Ultrasonography, Interventional

Substances

  • Cardiovascular Agents
  • Coated Materials, Biocompatible